Copyright © David Miller. All rights reserved.
Kenneth Blum, Ph.D., DHL
Creator of KB220Z (SynaptaGenX) and Chief Neuroscience Advisor for NuPathways, Inc.
Since 1995 when Dr. Blum retired from the University of Texas Health Science he has continued to be very active. He is the Scientific Director of the Path Medical Foundation and co-founder; Chairman and CSO of Geneus Health LLC. His concept of Reward Deficiency Syndrome published in Sage Encyclopedia of Abnormal Psychology (2017) has been embraced by leaders in addiction science and ASAM. Drs. Blum and Noble are credited with the seminal discovery of the association of the dopamine D2 receptor gene and addiction. He serves as Editor-in-Chief or co EIC for the Journal of Reward Deficiency Syndrome and Addiction Sciences; the Journal of Neuroimaging in Psychiatry and Neurology and the Journal of Systems & Integrative Neuroscience, as well as, the Editorial Boards of fourteen prestigious journals including Frontiers of Biosciences and Current Psychopharmacology. He is the Chief Scientific Advisor for Dominion Diagnostics, LLC North Kingstown Rhode Island, Nupathways Inc. and The Shores Treatment and Recovery Center and New Future Detox. He has published over 550 articles, abstracts, chapters, 17 books, holds numerous patents and many awards for his seminal discoveries. He is the founding President of United Scientific Group (USG). He is an honorary lifetime full professor of Psychology at the Eotvos Lorand University, Hungary. He also holds adjunct or voluntary professorships in the Departments of Psychiatry Keck School of Medicine, LA; University of Florida College of Medicine, Gainesville, FL; Wright State University, OH; and the Center for Clinical & Translational Science, College of Medicine, University of Vermont, VT and is Emritis Faculty Centre for Genomics and Applied Gene Technology, Institute of Integrative Omics and Applied Biotechnology (IIOAB), Nonakuri, Purba Medinipur, West Bengal, India. He is the PI recipient of a NIMH grant along with Marjorie Gondre- Lewis of Howard University.
1. Blum K. The effect of dopamine and other catecholamines on neuromuscular transmission. Arch Int Pharmacodyn Ther. 1969;181(2):297-306.
2. Blum K, Seifter E, Seifter J. The pharmacology of d- and l-carnitine and d- and l-acetylcarnitine. Comparison with choline and acetylcholine. J Pharmacol Exp Ther. 1971;178(2):331-8.
3. Blum K, Hamilton MG, Meyer EK, Hirst M, Marshall A. Isoquinoline alkaloids as possible regulators of alcohol addiction. Lancet. 1977;1(8015):799-800.
4. Blum K, Futterman S, Wallace JE, Schwertner HA. Naloxone-induced inhibition of ethanol dependence in mice. Nature. 1977;265(5589):49-51.
5. Blum K, Wallace JE. Effects of catecholamine synthesis inhibition on ethanol-induced withdrawal symptoms in mice. Br J Pharmacol. 1974;51(1):109-11.
6. Blum K, Calhoun W, Merritt J, Wallace JE. L-DOPA: effect on ethanol narcosis and brain biogenic amines in mice. Nature. 1973;242(5397):407-9.
7. Blum K, Briggs AH, Elston SF, DeLallo L, Sheridan PJ, Sar M. Reduced leucine-enkephalin--like immunoreactive substance in hamster basal ganglia after long-term ethanol exposure. Science. 1982;216(4553):1425-7.
8. Blum K, Briggs AH, Elston SF, DeLallo L., Walace JE. Ethanol preference as a function of genotype announts of [Met]- enkephalin. Proc Natl Acad Sci U S A . 1983;80(21):6510-6512.
9. Blum K, Braverman ER, Wu S, Cull JG, Chen TJ, Gill J, et al. Association of polymorphisms of dopamine D2 receptor (DRD2), and dopamine transporter (DAT1) genes with schizoid/avoidant behaviors (SAB). Mol Psychiatry. 1997;2(3):239-46.
10. Blum K, Noble EP, Sheridan PJ, Finley O, Montgomery A, Ritchie T, et al. Association of the A1 allele of the D2 dopamine receptor gene with severe alcoholism. Alcohol. 1991;8(5):409-16.
11. Blum K, Noble EP, Sheridan PJ, Montgomery A, Ritchie T, Jagadeeswaran P, et al. Allelic association of human dopamine D2 receptor gene in alcoholism. JAMA. 1990;263(15):2055-60.
12. Noble EP, Blum K, Ritchie T, Montgomery A, Sheridan PJ. Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch Gen Psychiatry. 1991;48(7):648-54.
13. Blum K, Han D, Femino J, Smith DE, Saunders S, Simpatico T, et al. Systematic evaluation of "compliance" to prescribed treatment medications and "abstinence" from psychoactive drug abuse in chemical dependence programs: data from the comprehensive analysis of reported drugs. PLoS One. 2014;9(9):e104275.
14. Febo M, Blum K, Badgaiyan RD, Perez PD, Colon-Perez LM, Thanos PK, et al. Enhanced functional connectivity and volume between cognitive and reward centers of naive rodent brain produced by pro-dopaminergic agent KB220Z. PLoS One. 2017;12(4):e0174774.
15. Blum K, Chen ALC, Thanos PK, Febo M, Demetrovics Z, Dushaj K, et al. Genetic addiction risk score (GARS) , a predictor of vulnerability to opioid dependence. Frontiers in bioscience (Elite edition). 2018;10:175-96